Definitive Healthcare Corp. filings document the regulatory disclosures of a public healthcare data and analytics software company. Recent Form 8-K reports furnish quarterly and annual financial-result releases covering revenue, net loss, adjusted profitability measures, cash flow, guidance, and impairment-related disclosures tied to the company’s subscription-based commercial intelligence platform.
The filing record also includes definitive proxy materials for annual stockholder matters, board elections, executive compensation, equity awards, and governance practices. Other material-event filings document board and committee composition changes, executive-role and compensation arrangements, and the termination of a nominating agreement affecting director-designation rights.
Coop Kevin reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. reported that Chief Executive Officer Kevin Coop received an equity award linked to 1,735,437 shares of Class A Common Stock in the form of restricted stock units. These RSUs vest 25% on March 1, 2027, then 6.25% every three months over the next three years, contingent on his continued service. Following this grant, Coop is reported as beneficially owning 5,291,989 shares of Class A Common Stock.
Definitive Healthcare Corp. executive chairman and 10% owner Jason Ronald Krantz reported an equity award. On February 24, 2026, he acquired 242,719 restricted stock units, each representing one share of Class A common stock, at no cost. These RSUs vest 100% on March 1, 2027, subject to his continued service. After this grant, he directly holds 1,258,758 shares. He also has indirect beneficial ownership of 450,000 shares through DH Holdings, formerly the Jason R. Krantz 2009 Trust, where he is the beneficiary.
Definitive Healthcare Corp. executive updates initial ownership report. EVP and Chief Data Officer Benjamin Graboske filed an amended Form 3 to reflect beneficial ownership of 4,045.654 shares of Class A Common Stock. A footnote explains these shares were mistakenly omitted from his original Form 3 and from two subsequent Forms 4.
Definitive Healthcare Corp. provides a SaaS healthcare data and analytics platform that supports commercial decisions across life sciences, providers and diversified healthcare customers. It serves approximately 2,330 customers and derives 96% of its revenue from subscriptions.
For the year ended December 31, 2025, the company reported a net loss of $199.3 million, an improvement from a net loss of $591.4 million in 2024. As of December 31, 2025, its workforce totaled 686 employees across the U.S., Europe and India. The report emphasizes intense competition, reliance on third‑party data, evolving privacy and security rules, macroeconomic pressures on customer spending, and execution risks around AI, innovation, acquisitions and restructuring.
Definitive Healthcare reported mixed 2025 results with improving profitability metrics but lower revenue. Q4 2025 revenue was $61.5 million, down 1% from $62.3 million in Q4 2024, while Adjusted EBITDA rose slightly to $18.0 million, or 29% of revenue, from $17.5 million and 28% a year earlier. Q4 net loss narrowed sharply to $17.1 million, including $19.5 million of goodwill impairment, compared with an $84.7 million loss including $97.1 million of impairment in Q4 2024.
For full year 2025, revenue was $241.5 million versus $252.2 million in 2024. Net loss was $199.3 million, including $196.1 million in goodwill impairment, improving from a $591.4 million loss with $688.9 million of impairment in 2024. Adjusted EBITDA was $70.4 million, or 29% of revenue, down from $79.1 million and a 31% margin. Operating cash flow reached $53.8 million and Unlevered Free Cash Flow was $54.9 million.
For 2026, the company guides revenue to $220.0–$226.0 million, Adjusted EBITDA to $53.0–$58.0 million with a 24–26% margin, and Adjusted Net Income to $21.0–$26.0 million, or $0.14–$0.17 per diluted share.
Goldman Sachs Group and Goldman Sachs & Co. LLC report beneficial ownership of 5,935,933 shares of Definitive Healthcare Corp Class A common stock, representing 5.7% of the class as of 12/31/2025.
They report shared voting power over 5,934,807 shares and shared dispositive power over 5,935,933 shares. The firms state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Definitive Healthcare.
Definitive Healthcare Corp. Executive Chairman Jason Ronald Krantz reported a tax-related share withholding on February 1, 2026. The issuer withheld 44,545 shares of Class A Common Stock at $2.32 per share to cover tax obligations linked to vesting of previously reported restricted stock units.
After this transaction, Krantz beneficially owned 1,016,039 Class A shares directly and 450,000 shares indirectly through DH Holdings (formerly the Jason R. Krantz 2009 Trust), where he is the beneficiary.
Definitive Healthcare Corp. reported a routine insider tax withholding transaction by its Chief Financial Officer. On 02/01/2026, CFO Casey Heller had 1,469 shares of Class A common stock withheld by the company at $2.32 per share to cover tax obligations tied to vesting restricted stock units. After this withholding, Heller beneficially owned 1,274,021 Class A common shares directly.
Definitive Healthcare Corp. reported that its Chief Financial Officer, Casey Heller, received an equity grant of 195,313 Class A common shares in the form of restricted stock units on January 5, 2026. These RSUs carry a grant price of $0 per share, reflecting a compensation award rather than an open-market purchase.
Each RSU represents the right to receive one share of Class A common stock, with 50% vesting on January 1, 2027. The remaining half vests in equal quarterly installments over the following 12 months, conditioned on Heller’s continued service with the company. After this grant, Heller directly beneficially owns 1,275,490 shares of Class A common stock.
Definitive Healthcare Corp. reported Q3 2025 revenue of $60.0 million versus $62.7 million a year ago, with gross profit of $46.0 million. Loss from operations was $8.7 million. Net loss attributable to Definitive Healthcare narrowed to $14.8 million from $130.9 million in Q3 2024, which included a large impairment.
Year to date, revenue was $180.0 million and operating cash flow was $51.1 million. The company reduced its 2021 Term Loan principal to $168.4 million and had no borrowings on its $50.0 million revolver, with $49.7 million available after a standby letter of credit. Total assets were $755.5 million, including goodwill of $216.8 million following a $176.5 million non‑cash goodwill impairment recorded in Q1 2025. Deferred revenue was $92.0 million, and remaining performance obligations totaled $247.3 million. Class A shares outstanding were 103,011,649 as of September 30, 2025.